ALSO READAurobindo Pharma acquires Portuguese pharma company - Generis Farmaceutica S.A. Aurobindo Pharma gains on reports of USFDA nod for 2 generic drugs Aurobindo Pharma gets final approval for Abacavir Sulfate and Lamivudine Tablets Aurobindo Pharma fixes record date for second interim dividend Aurobindo Pharma announces plans to acquire Generis Farmaceutica SA in Portugal
From USFDAAurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm. Sevelamer Carbonate oral suspension, a therapeutic equivalent generic version of Genzyme's Renvela oral suspension.
The product is being launched immediately.
Sevelamer Carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approved product has an estimated market size of US$ 140 million for the twelve months ending April 2017 according to IMS.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)